CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

procarbazine

Trade name: matulane

Small moleculeapproved

Approved

Jul 22, 1969

Procarbazine is a chemotherapy medication used for the treatment of Hodgkin's lymphoma and brain cancers. For Hodgkin's it is often used together with mechlorethamine, vincristine, and prednisone while for brain cancers such as glioblastoma multiforme it is used with lomustine and vincristine. Procarbazine inhibits DNA, RNA, and protein synthesis by inhibiting transmethylation of methionine into transfer RNA; may also damage DNA directly through alkylation. Common side effect include low blood cell counts and vomiting. Other side effects include tiredness and depression. — NCATS

Clinical trial activity

82 trials · 124 clinical orgs · 1 marketing orgs

Phase 1
4
Phase 2
70
Phase 3
31
Phase 4
1

Earliest trial started Feb 1, 1989 (NCT00002463)

Timeline

1960s

  1. Jul 22, 1969

    Leadiant Biosciences, Inc. — Earliest FDA Approval

  2. Jul 22, 1969

    Leadiant Biosciences, Inc. — NDA Secondary Org

  3. Jul 22, 1969

    Leadiant Biosciences, Inc. — NDA Organization

1980s

  1. Jan 1, 1989

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 1989

    Earliest Phase 3 Sponsor(trial)

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • DNAINHIBITOR

    DNA inhibitor

Approval history

  • approvedPriority reviewJul 22, 1969

Chemistry & pharmacology

Loading structure…

SMILES

CNNCc1ccc(C(=O)NC(C)C)cc1
Mol. weight
221.3 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warningProdrug

Sources

Also known as

  • 1-methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
  • 1-methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
  • 2-(p-isopropylcarbamoylbenzyl)-1-methylhydrazine
  • 2-(p-isopropylcarbamoylbenzyl)-1-methylhydrazine
  • 4-((2-methylhydrazino)methyl)-n-isopropylbenzamide
  • 4-((2-methylhydrazino)methyl)-n-isopropylbenzamide
  • ibenzmethyzine
  • matulane
  • matulane
  • matulane
  • n-(1-methylethyl)-4-((2-methylhydrazino)methyl)benzamide
  • n-(1-methylethyl)-4-((2-methylhydrazino)methyl)benzamide
  • n-4-isopropylcarbamoylbenzyl-n'-methylhydrazine
  • n-4-isopropylcarbamoylbenzyl-n'-methylhydrazine
  • natulan
  • natulan
  • n-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
  • n-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
  • n-isopropyl-p-(2-methylhydrazinomethyl)-benzamide
  • n-isopropyl-p-(2-methylhydrazinomethyl)-benzamide
  • n-isopropyl-α-(2-methylhydrazino)-p-toluamide
  • n-isopropyl-α-(2-methylhydrazino)-p-toluamide
  • p-(2-methylhydrazinomethyl)-n-isopropylbenzamide
  • p-(2-methylhydrazinomethyl)-n-isopropylbenzamide
  • procarbazin
  • procarbazin
  • procarbazina
  • procarbazina
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine
  • procarbazine hcl
  • procarbazine hcl
  • procarbazine hcl
  • procarbazine hydrochloride
  • procarbazine hydrochloride
  • procarbazine hydrochloride
  • procarbazine hydrochloride
  • procarbazinum
  • procarbazinum
  • ro-46467/1
  • ro-46467/1
  • ro-4646711
  • ro-4646711

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07015242Phase 2Nov 6, 2025Bristol-Myers Squibb
NCT06830421Phase 3Aug 9, 2023German Federal Ministry of Education and Research, Ludwig Maximilians University, University of Duesseldorf, University of Freiburg, University of Regensburg, University of Tuebingen
NCT05675410Phase 3May 11, 2023National Cancer Institute (NCI), State University of New York, Buffalo
NCT05008224Phase 2Oct 7, 2021Merck
NCT04702581Phase 3Jun 30, 2021University of Lyon
NCT05425654Phase 2May 17, 2021Russian Academy of Medical Sciences
NCT04022980Phase 1Jul 25, 2019Bristol-Myers Squibb, University of North Carolina at Chapel Hill, Wake Forest University
NCT03495960Phase 2Oct 1, 2018International Extranodal Lymphoma Study Group, The Foundation Institute San Raffaele G. Giglio of Cefalù
NCT01775475Phase 2Sep 1, 2016AIDS Malignancy Consortium, National Cancer Institute (NCI), The EMMES Corporation
NCT02661503Phase 3Jul 1, 2016University of Cologne
NCT02800447N/AJun 1, 2016Lee's Pharmaceutical
NCT02444000Phase 3Jun 1, 2015University of Paris
NCT02298283Phase 2Apr 1, 2015The Lymphoma Academic Research Organisation, The Lymphoma Study Association
NCT02333513N/AFeb 1, 2015Capital Medical University, Hebei University
NCT01652261Phase 3May 1, 2013European Organisation for Research and Treatment of Cancer, Netherlands Cancer Institute, Polish Lymphoma Research Group, Radboud University, University of Copenhagen, University of Groningen
NCT01569204Phase 2Oct 1, 2012University of Cologne
NCT01737346Phase 2Oct 1, 2012Catholic University of Korea, National Cancer Center, Korea
NCT01390584Phase 2Apr 2, 2012American College of Radiology, Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Stanford University
NCT01356680Phase 3Dec 1, 2011University of Cologne
NCT01399372Phase 2Sep 1, 2011Cornell University, National Cancer Institute (NCI), NRG Oncology, Radiation Therapy Oncology Group
Showing 20 of 82 trials
Page 1 / 5

Organizations

Research & Development (124)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government27831989
University of CologneAcademic/Hospital9821998
European Organisation for Research and Treatment of CancerAcademic/Hospital8711989
Cornell UniversityAcademic/Hospital7521996
The Lymphoma Study AssociationAcademic/Hospital5021998
Case Western Reserve UniversityAcademic/Hospital4411997
Eastern Cooperative Oncology GroupAcademic/Hospital4121994
Mayo ClinicAcademic/Hospital4021994
University of Texas at HoustonAcademic/Hospital4321989
Canadian Cancer Trials GroupAcademic/Hospital3011994
Children's Cancer and Leukaemia GroupAcademic/Hospital3322000
Institut BergoniéAcademic/Hospital3011993
Ludwig Maximilians UniversityAcademic/Hospital3022004
Medical Research CouncilGovernment3111996
Radboud UniversityAcademic/Hospital3011989
Radiation Therapy Oncology GroupAcademic/Hospital3321994
Southwest Oncology GroupAcademic/Hospital3121994
University of ParisAcademic/Hospital3222007
Wake Forest UniversityAcademic/Hospital3231998
Bristol-Myers SquibbFor profit2122019
124 organizations
Page 1 / 7

Marketing (2)

OrganizationOrg typeRelationshipDate
Leadiant Biosciences, Inc.For profitNDA2Jul 22, 1969
Leadiant Biosciences, Inc.For profitNDAJul 22, 1969